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ab
stract
PURPOSE The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-
negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models,
and drug sensitivity has been associated with activation of PI3K or AKT and/or deletions of PTEN. The PAKT trial
was designed to evaluate the safety and efficacy of adding capivasertib to paclitaxel as first-line therapy
for TNBC.
PATIENTS AND METHODS This double-blind, placebo-controlled, randomized phase II trial recruited women with
untreatedmetastatic TNBC. A total of 140 patients were randomly assigned (1:1) to paclitaxel 90mg/m2 (days 1,
8, 15) with either capivasertib (400 mg twice daily) or placebo (days 2-5, 9-12, 16-19) every 28 days until
disease progression or unacceptable toxicity. The primary end point was progression-free survival (PFS).
Secondary end points included overall survival (OS), PFS and OS in the subgroup with PIK3CA/AKT1/PTEN
alterations, tumor response, and safety.
RESULTS Median PFS was 5.9 months with capivasertib plus paclitaxel and 4.2 months with placebo plus
paclitaxel (hazard ratio [HR], 0.74; 95% CI, 0.50 to 1.08; 1-sided P = .06 [predefined significance level, 1-sided
P = .10]). Median OS was 19.1 months with capivasertib plus paclitaxel and 12.6 months with placebo plus
paclitaxel (HR, 0.61; 95%CI, 0.37 to 0.99; 2-sided P = .04). In patients with PIK3CA/AKT1/PTEN-altered tumors
(n = 28), median PFS was 9.3 months with capivasertib plus paclitaxel and 3.7 months with placebo plus
paclitaxel (HR, 0.30; 95% CI, 0.11 to 0.79; 2-sided P = .01). The most common grade $ 3 adverse events in
those treated with capivasertib plus paclitaxel versus placebo plus paclitaxel, respectively, were diarrhea (13% v
1%), infection (4% v 1%), neutropenia (3% v 3%), rash (4% v 0%), and fatigue (4% v 0%).
CONCLUSION Addition of the AKT inhibitor capivasertib to first-line paclitaxel therapy for TNBC resulted in
significantly longer PFS and OS. Benefits were more pronounced in patients with PIK3CA/AKT1/PTEN-altered
tumors. Capivasertib warrants further investigation for treatment of TNBC.
J Clin Oncol 38:423-433. © 2019 by American Society of Clinical Oncology
INTRODUCTION
Triple-negative breast cancer (TNBC) accounts for
approximately 10% to 15% of all breast cancers and is
defined by the absence of expression of the estrogen
receptor (ER), progesterone receptor (PgR), and
nonamplified human epidermal growth factor recep-
tor 2 (HER2) expression.1 TNBC is a heterogeneous
disease, with subtypes characterized by distinct
pathologic, genetic, and clinical features.2,3 Chemo-
therapy remains the mainstay of treatment, but ben-
efits are frequently short lived, with rapid development
of resistance.1,4 Treatment results for patients with
metastatic TNBC remain poor compared with results
for those with other subtypes, with a median survival of
approximately 1 year, and novel treatment approaches
that target biologically defined subpopulations are
urgently needed.1,4
The phosphatidylinositol 3-kinase (PI3K)/AKT signaling
pathway is frequently activated in TNBC through acti-
vating mutations in PIK3CA or AKT1 and/or inactivating
alterations in PTEN.5-7 In addition, deficient expression
of PTEN is a common finding in TNBC and has been
associated with a higher degree of AKT pathway
activation.8,9 Additional ways of activating the PI3K/AKT
pathway include lack of INPP4B expression and/or
amplification of PIK3CA, AKT1, AKT2, or AKT3.5,7
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AKT is the central node of multiple signaling pathways
promoting cell survival, growth, invasion, and migration.9,10
Activation of the PI3K/AKT pathway has been associated
with poor prognosis and resistance.11-14 Induction of AKT
activity by chemotherapy can also be an early compensatory
mechanism that can be exploited to increase the efficacy of
chemotherapy.Multiple lines of preclinical investigation have
demonstrated that inhibition of AKT increases the activity of
chemotherapy in TNBC and can overcome resistance.15
Capivasertib (AZD5363) is a potent highly selective, orally
active small-molecule kinase inhibitor with similar activity
against the isoforms AKT1, AKT2, and AKT3.16,17 Cap-
ivasertib has shown preclinical activity in TNBC models,
with activation of PI3K or AKT and/or deletions of PTEN, but
increased activity has been seen with alterations of PIK3CA/
AKT1/PTEN.16,18,19 Preclinical TNBC models have also
demonstrated synergistic activity between capivasertib and
taxane-based chemotherapy.16,19
Most preclinical and clinical applications of PI3K/AKT
pathway inhibitors use continuous daily dosing. However,
intermittent administration has been explored to maximize
the therapeutic benefit and reduce toxicities by allowing for
recovery of nontarget tissues during dosing breaks.20-22
Phase I studies established the maximum tolerated doses
for continuous daily and intermittent dosing of capivasertib,
with substantial activity demonstrated for both schedules.23,24
On the basis of the accumulated efficacy and safety data, the
intermittent schedule (4 days on, 3 days off) of capivasertib
was selected for further clinical development.
The PAKT trial was designed to evaluate whether addition of
capivasertib can increase progression-free survival (PFS)
and other measures of antitumor activity of paclitaxel in
women with metastatic TNBC who have not received prior
therapy for metastatic disease. The study was also
designed to evaluate whether PIK3CA/AKT1/PTEN alter-
ations can define a subgroup with increased benefit from
the combination.
PATIENTS AND METHODS
PAKT was an investigator-led, placebo-controlled, random-
ized phase II trial performed in 42 academic medical centers
in the United Kindom, South Korea, France, Hungary,
Romania, and Georgia. Eligible patients had histologically
confirmed, metastatic or locally advanced TNBC (defined as
, 1% of tumor cell expression of ER or PgR on immuno-
histochemistry [IHC] and negative HER2 status, defined as
0 or 1+ intensity on IHC or no evidence of HER2 gene am-
plification on in situ hybridization [HER2/CEP17 ratio, 2.0])
not amenable to curative resection. Previous systemic therapy
for locally advanced or metastatic disease was not permitted,
but previous adjuvant or neoadjuvant chemotherapy was
allowed as long as taxane-based therapy had been com-
pleted $ 12 months before random assignment. Patients
were required to have measurable disease according to
RECIST (version 1.1) or lytic bone lesions in the absence
of measurable disease. Patients had to have adequate
hematologic, hepatic, and renal function and an Eastern
Cooperative Oncology Group performance status of 0 to 2.
Patients with brain metastases were excluded unless they
had completed treatment, were asymptomatic, and had
been stable for 3 months. Patients were excluded if they
had significant pulmonary dysfunction, significant cardiac
disease, QT prolongation, ongoing grade $ 2 peripheral
neuropathy, any condition that would interfere with enteral
absorption, or clinically significant abnormalities of glucose
metabolism, defined as diagnosis of diabetes mellitus type I
or II, glycosylated hemoglobin (hemoglobin A1C)$ 8.0% at
screening, or fasting plasma glucose $ 7.0 mmol/L. Ad-
ditionally, patients with previous treatment with PI3K, AKT,
or mammalian target of rapamycin inhibitors were excluded.
All patients provided written informed consent. The relevant
institutional review board or ethics committee for each
participating center approved the study, which was con-
ducted in accordance with the principles of Good Clinical
Practice, the provisions of the Declaration of Helsinki, and
other applicable local regulations.
Patients were randomly assigned (1:1) to receive paclitaxel
plus capivasertib or paclitaxel plus placebo. Stratification
was by number of metastatic sites (, 3 v $ 3) and interval
from the end of prior adjuvant or neoadjuvant chemo-
therapy (# 12 v . 12 months v no prior chemotherapy).
Paclitaxel was administered as a once-per-week in-
travenous infusion of 90 mg/m2 over approximately 1 hour
on days 1, 8, and 15 of each 28-day treatment cycle.
Capivasertib 400 mg or placebo was administered orally
twice per day on an intermittent weekly dosing schedule,
with treatment on days 2 to 5 of weeks 1, 2, and 3 within
each 28-day cycle. All treatments were continued until
disease progression, development of unacceptable toxicity,
or withdrawal of consent. If paclitaxel treatment was dis-
continued before disease progression, patients could
continue to receive capivasertib or placebo alone. In case of
adverse events (AEs), capivasertib or placebo could be
reduced to 320 mg twice per day and subsequently to
240 mg twice per day. Capivasertib or placebo could be
interrupted for up to 4 weeks for toxicity.
Tumor assessments included computed tomography scan-
ning or magnetic resonance imaging of the chest, abdomen,
and pelvis at baseline, every 8 weeks during treatment, and
at progression. Patients who discontinued treatment for any
reason other than progression were required to follow the
same schedule of assessments until progression, initiation of
another treatment, death, or withdrawal of consent. All scans
were sent for central radiologic review.
All patients were required to provide a representative
formalin-fixed, paraffin-embedded tumor specimen from
the most recent biopsy. Tumor tissue was centrally
assessed for genetic alterations of PIK3CA, PTEN, and
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AKT1 using a next-generation sequencing (NGS) assay
(Appendix Fig A1, online only). Tumors were considered
PIK3CA/AKT1/PTEN altered if they had$ 1 of the following
mutations: activating mutation in AKT1 (E17K) or PIK3CA
(R88Q, N345K, C420R, E542X, E545X, Q546X, M1043I,
H1047X, G1049R mutations [X represents any change in
amino acid residue]) and/or a deleterious mutation in PTEN
or loss of the PTEN gene. Cases in which none of these
mutations were identified were classified as PIK3CA/AKT1/
PTEN nonaltered.
The primary end point was PFS by local assessment. PFS
was defined as time from random assignment to disease
progression or death resulting from any cause, whichever
occurred first. Secondary end points included overall
survival (OS), overall response rate, clinical benefit rate,
durations of response and clinical benefit, PFS and other
efficacy end points in patients with PIK3CA/AKT1/PTEN-
altered and -nonaltered tumors, and safety. For all time-to-
event analyses performed, patients who did not experience
an event were right censored; PFS and duration of response
were censored on the last date the patient was known to
be progression free; OS was censored at the date of last
contact.
The sample size was calculated to provide 80% power at
a 10% significance level (1 sided) to detect an improve-
ment in PFS in patients allocated to capivasertib plus
paclitaxel with a hazard ratio (HR) of 0.67. With an esti-
mated recruitment time of 24 months and a minimum
follow-up of 12 months, a total of 111 PFS events were
needed. To allow for loss to follow-up and imprecision in the
estimated event rate, 140 patients were recruited.
Comparisons between arms were performed using Fisher’s
exact test for categorical variables and the Wilcoxon rank
sum test for continuous variables. All efficacy analyses were
performed on an intent-to-treat (ITT) basis, including all
randomly assigned patients, regardless of whether they
were later found to be ineligible, be in violation of the
protocol violator, or have received the wrong treatment.
Survival end points were shown graphically with Kaplan-
Meier plots, and treatment comparisons were made with
the log-rank test. HRs were obtained from Cox proportional
hazards regression models, with HRs of , 1 favoring
capivasertib plus paclitaxel. HRs and treatment compari-
sons were stratified by the 2 randomization stratification
factors for analyses of the ITT population. Analyses of
Patients
screened 
(N = 175) 
Randomly assigned
(n = 140)
Assigned to
Paclitaxel +
Capivasertib 
(n = 70) 
Assigned to
Paclitaxel +
Placebo 
(n = 70) 
Treated with
Paclitaxel +
Capivasertib 
(n = 68) 
Treated with
Paclitaxel +
Placebo 
(n = 70) 
Still on
treatment 
(n = 6) 
Still on
treatment 
(n = 6) 
2 did not receive treatment
Discontinued                          (n = 62)
    Progressed                        (n = 49)
    Died (with/without PD)     (n = 33)
    Had AEs                              (n = 6)
    Decision by pt or                  (n = 9)
       investigator 
Discontinued                          (n = 64)
    Progressed                         (n = 58)
    Died (with/without PD)      (n = 41)
    Had AEs                                (n = 4)
    Decision by pt or                  (n = 8) 
       investigator
FIG 1. Trial CONSORT diagram. AE, adverse event; PD, progressive disease; pt, patient.
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patients with PIK3CA/AKT1/PTEN-altered and -nonaltered
tumors and other subgroup analyses were not stratified.
Safety analyses included all patients who received$ 1 dose
of trial treatment (as treated population), with patients an-
alyzed according to the treatment they actually received. The
worst grade of AE during trial treatment was reported. Rel-
ative dose-intensity for each study drug was calculated using
the actual amount of study drug received in milligrams di-
vided by the expected amount of study drug in milligrams.
RESULTS
Between May 2014 and June 2017, 140 patients were
randomly assigned (Fig 1) at 42 sites in 6 countries: 70
patients to capivasertib plus paclitaxel and 70 to placebo
plus paclitaxel. With the exception of visceral disease
(P = .04), no significant differences were observed in
baseline patient or tumor characteristics between treat-
ment arms (Table 1). Median age was 54 years; 69% of
patients had visceral involvement; 46% had metastases in
$ 3 organs; a majority of patients had received adjuvant or
neoadjuvant chemotherapy (77%), with 57% of patients
having received prior taxane-based treatment; 18 patients
presented with de novo metastatic disease (Appendix Fig
A2, online only).
At the data cutoff date (January 2018), 6 patients in each
group were still receiving study treatment. A higher per-
centage of patients in the capivasertib group had$ 1 dose
interruption or delay (34% v 15%; P = .02) or required
a dose reduction (17% v 2%; P, .01), although there was
TABLE 1. Patient Demographic and Disease Characteristics at Baseline
Characteristic
ITT Population PIK3CA/AKT1/PTEN-Altered Subgroup
No. (%)*
P†
No. (%)*
P†
Paclitaxel + Capivasertib
(n = 70)
Paclitaxel + Placebo
(n = 70)
Paclitaxel + Capivasertib
(n = 17)
Paclitaxel + Placebo
(n = 11)
Age, years .09 .56
Median 55.5 51.9 60.5 60.6
IQR 48.4-62.3 40.8-60.7 57.1-67.1 36.0-65.2
ECOG performance status .48 .51
0 43 (61.4) 48 (68.6) 10 (58.8) 9 (81.8)
1 26 (37.1) 22 (31.4) 6 (35.3) 2 (18.2)
2 1 (1.4) 0 1 (5.9) 0
Visceral disease .04 1.00
Yes 42 (60.0) 54 (77.1) 12 (70.6) 8 (72.7)
No 28 (40.0) 16 (22.9) 5 (29.4) 3 (27.3)
Sites of metastatic disease
Liver 17 (24.3) 21 (30.0) .57 6 (35.3) 5 (45.5) .70
Lung 35 (50.0) 45 (64.3) .12 9 (52.9) 6 (54.5) 1.00
Bone 29 (41.4) 28 (40.0) 1.00 11 (64.7) 5 (45.5) .44
Lymph node/soft tissue 49 (70.0) 51 (72.9) .85 7 (41.2) 10 (90.9) .02
No. of metastatic sites 1.00 .70
, 3 37 (52.9) 38 (54.3) 11 (64.7) 6 (54.5)
$ 3 33 (47.1) 32 (45.7) 6 (35.3) 5 (45.5)
Prior taxanes 1.00 .46
Yes 40 (57.1) 40 (57.1) 9 (52.9) 4 (36.4)
No 30 (42.9) 30 (42.9) 8 (47.1) 7 (63.6)
Adjuvant or neoadjuvant chemotherapy 1.00 .12
End # 12 months 4 (5.7) 4 (5.7) 1 (5.9) 0
End . 12 months 50 (71.4) 50 (71.4) 11 (64.7) 4 (36.4)
No prior chemotherapy 16 (22.9) 16 (22.9) 5 (29.4) 7 (63.6)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; ITT, intent to treat.
*All percentages are based on the total No. of patients in that arm.
†P values are 2-sided.
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no difference in median relative dose-intensity for paclitaxel
(P = .07) or capivasertib or placebo (P = .46) between
groups (Table 2). Median duration of treatment was longer
in the capivasertib group compared with the placebo group.
Frequency of AEs was comparable between treatment
groups (P = .27), but the incidence of severe AEs (grade 3-4)
was significantly higher with capivasertib (P , .01). The
most common AEs with capivasertib were GI effects (di-
arrhea, stomatitis, decreased appetite, nausea, vomiting),
alopecia, neuropathy, fatigue, infection, and rash (Table 3).
These were typically grade 1 or 2. Grade$ 3 AEs occurred
in 54% of patients (37 of 68) in the capivasertib group and
26% (18 of 70) in the placebo group (Table 3). The most
common grade 3 to 4 AEs in those treated with capivasertib
plus paclitaxel versus placebo plus paclitaxel, respectively,
were diarrhea (13% v 1%), fatigue (4% v 0%), rash (4% v
0%), infection (4% v 1%), and neutropenia (3% in both
arms).
After a median follow-up of 18.2 months (95% CI, 13.5 to
24.0), 112 progression events were reported: 51 patients
assigned to capivasertib plus paclitaxel and 61 patients
assigned to placebo plus paclitaxel. Median PFS was
5.9 months (95% CI, 3.8 to 7.5) with capivasertib plus
paclitaxel and 4.2 months (95% CI, 3.5 to 5.2) with placebo
plus paclitaxel (HR, 0.74; 95% CI, 0.50 to 1.08; 1-sided
P = .06; 2-sided P = 0.11; predefined significance level,
1-sided P = .10; Fig 2A).
Tumor tissue samples were assessed centrally for PIK3CA/
AKT1/PTEN alterations in 112 patients (80% of the ITT
population). In the remaining 28 patients (20%), PIK3CA/
AKT1/PTEN status could not be determined because of
insufficient sample or assay failure. A total of 28 samples
(25% of analyzed samples) had activating PIK3CA/AKT1
mutations or inactivating PTEN alterations. Biomarker-
assessable populations for PIK3CA/AKT1/PTEN alter-
ations showed baseline characteristics similar to those of
the ITT population.
Prespecified analyses in the subgroup of patients with
PIK3CA/AKT1/PTEN-altered tumors showed a median PFS
of 9.3 months (95% CI, 3.7 to 17.7) with capivasertib plus
paclitaxel and 3.7 months (95% CI, 1.9 to 5.9) with placebo
plus paclitaxel (HR, 0.30; 95% CI, 0.11 to 0.79; 2-sided
P = .01; Fig 2B). Exploratory analysis of the interaction
between PIK3CA/AKT1/PTEN alteration and treatment
showed a significantly reduced risk of 66% (HR, 0.34; 95%
CI, 0.13 to 0.93; 2-sided P = .04) for those patients who had
PIK3CA/AKT1/PTEN alteration and received capivasertib.
In patients with PIK3CA/AKT1/PTEN-nonaltered tumors,
median PFS was 5.3 months (95% CI, 3.5 to 7.3) with
capivasertib plus paclitaxel and 4.4 months (95% CI, 3.5 to
5.7) with placebo plus paclitaxel (HR, 1.13; 95%CI, 0.70 to
1.82; 2-sided P = .61; Fig 2C).
On the basis of central review assessments, median PFS
was 5.5 months (95% CI, 3.8 to 7.5) with capivasertib plus
paclitaxel and 3.6 months (95% CI, 3.2 to 4.8) with placebo
plus paclitaxel (HR, 0.64; 95% CI, 0.43 to 0.95; 1-sided
P = .01; 2-sided P = .02; predefined significance level,
1-sided P = .10). In patients with PIK3CA/AKT1/PTEN-
altered tumors, median PFS was 9.3 months (95% CI, 3.8
to not reached [NR]) with capivasertib plus paclitaxel com-
pared with 3.6 months (95% CI, 1.4 to 5.3) with placebo
plus paclitaxel (HR, 0.14; 95% CI, 0.05 to 0.44; 2-sided
P , .001; Appendix Fig A3, online only).
Secondary end points of objective response and clinical
benefit rate are summarized in Table 4. Median duration of
response was 7.6 months (95% CI, 5.6 to 12.5) with
capivasertib plus paclitaxel and 7.3 months (95% CI, 3.5 to
9.1) with placebo plus paclitaxel. In patients with PIK3CA/
AKT1/PTEN-altered tumors, median duration of response
was 13.3months (95%CI, 8.9 to NR) with capivasertib plus
paclitaxel and 3.5 months (95%CI, 3.5 to NR) with placebo
plus paclitaxel.
At the time of data cutoff, 74 patients had died (53%):
33 (47%) in the capivasertib plus paclitaxel group and
TABLE 2. Treatment Summary
Treatment Compliance
Paclitaxel + Capivasertib
(n = 65)
Paclitaxel + Placebo
(n = 65) P*
Patients with $ 1 dose interruption/delay because of AE, No. (%)† 22 (33.8) 10 (15.4) .02
Patients with $ 1 dose reduction of capivasertib or placebo, No. (%)† 11 (16.9) 1 (1.5) , .01
Median (IQR) duration of treatment, months
Capivasertib or placebo 4.8 (1.7-7.5) 4.1 (2.2-7.6) .86
Paclitaxel 4.8 (1.9-6.1) 3.7 (1.7-5.4) .50
Median (IQR) relative dose-intensity, %
Capivasertib or placebo 91.1 (80.6-100.0) 93.8 (86.4-100.0) .46
Paclitaxel 96.6 (81.8-100.0) 100.0 (91.7-100.0) .07
NOTE. Patients are presented based on the treatment they received.
Abbreviations: AE, adverse event; IQR, interquartile range.
*P values are 2-sided.
†All percentages are based on the total No. of patients in that arm with complete compliance data.
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41 (59%) in the placebo plus paclitaxel group. Median OS
was 19.1 months (95% CI, 10.9 to 20.9) with capivasertib
plus paclitaxel and 12.6months (95%CI, 10.4 to 16.9) with
placebo plus paclitaxel (HR, 0.61; 95% CI, 0.37 to 0.99;
2-sided P = .04; Fig 3A). In the PIK3CA/AKT1/PTEN-altered
subgroup, median OS was NR (95% CI, 10.2 to NR) in
patients receiving capivasertib versus 10.4 months (95%
CI, 4.0 to NR) in those receiving placebo (HR, 0.37; 95%
CI, 0.12 to 1.12; 2-sided P = .07; Fig 3B). In patients with
PIK3CA/AKT1/PTEN-nonaltered tumors, median OS was
16.6 months (95% CI, 10.8 to 20.4) with capivasertib
versus 13.2 months (95% CI, 10.8 to 17.3) with placebo
(HR, 0.84; 95% CI, 0.48 to 1.49; 2-sided P = .56; Fig 3C).
DISCUSSION
This investigator-led, placebo-controlled, double-blind,
randomized trial showed that PFS and OS were longer
in patients who received the AKT inhibitor capivasertib
compared with those who received placebo. The primary
end point of PFS did not obtain the prespecified target HR
(0.67), as per sample size calculations, when measured
based on investigator assessments (HR, 0.74); however,
this was achieved when measured based on central review
assessments (HR, 0.64). Although the increase in median
PFS was relatively small in the overall population, the
benefits in patients with PIK3CA/AKT1/PTEN-altered tu-
mors were more pronounced, with a 5.6-month increase in
median PFS and 9.8-month increase in duration of re-
sponse. The addition of capivasertib resulted in a signifi-
cant increase in OS, from 12.6 to 19.1 months; the OS
benefit was also more pronounced in the PIK3CA/AKT1/
PTEN-altered subgroup.
The results of PAKT are remarkably consistent with the
results of the LOTUS study, providing additional evidence
TABLE 3. AEs Occurring in $ 8% of Patients in $ 1 Treatment Group
AE
No. (%)*
P†
Paclitaxel + Capivasertib
(n = 68)
Paclitaxel + Placebo
(n = 70)
All Grades Grade 3/4 All Grades Grade 3/4 All Grades Grade 3/4
Patients with $ 1 AE 66 (97.1) 37 (54.4) 64 (91.4) 18 (25.7) 0.27 , 0.01
Diarrhea 49 (72.1) 9 (13.2) 19 (27.1) 1 (1.4) , 0.01 , 0.01
Fatigue 30 (44.1) 3 (4.4%) 18 (25.7) 0 0.03 0.12
Nausea 24 (35.3) 1 (1.5) 23 (32.9) 0 0.86 0.49
Rash 28 (41.2) 3 (4.4) 11 (15.7) 0 , 0.01 0.12
Neuropathy 17 (25.0) 1 (1.5) 13 (18.6) 0 0.41 0.49
Stomatitis 18 (26.5) 1 (1.5) 10 (14.3) 0 0.09 0.49
Infection 15 (22.1) 3 (4.4) 10 (14.3) 1 (1.4) 0.27 0.36
Decreased appetite 14 (20.6) 0 8 (11.4) 0 0.17 1.00
Alopecia 11 (16.2) 0 9 (12.9) 0 0.63 1.00
Vomiting 13 (19.1) 1 (1.5) 6 (8.6) 1 (1.4) 0.09 1.00
Constipation 5 (7.4) 0 10 (14.3) 0 0.27 1.00
Abdominal pain 7 (10.3) 0 7 (10.0) 0 1.00 1.00
Dry skin 10 (14.7) 0 2 (2.9) 0 0.02 1.00
Dyspnoea 6 (8.8) 0 5 (7.1) 0 0.76 1.00
Headache 8 (11.8) 0 3 (4.3) 0 0.13 1.00
Edema 6 (8.8) 0 4 (5.7) 0 0.53 1.00
Dysgeusia 7 (10.3) 0 3 (4.3) 0 0.20 1.00
Joint pain 2 (2.9) 0 6 (8.6) 0 0.27 1.00
Neutropenia 6 (8.8) 2 (2.9) 2 (2.9) 2 (2.9) 0.16 1.00
Cough 1 (1.5) 0 6 (8.6) 0 0.12 1.00
Hyperglycemia 6 (8.8) 1 (1.5) 1 (1.4) 0 0.06 0.49
NOTE. Worst toxicity for each patient during the entire treatment is reported. AE instances with missing grade are not included in table.
Abbreviation: AE, adverse event.
*All percentages are based on the total No. of patients in that arm who received$ 1 dose of the study drug, with patients analyzed according to
the treatment they actually received (safety population).
†P values are 2-sided.
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for the role of AKT inhibitors in TNBC.25 LOTUSwas a phase
II study that evaluated the AKT inhibitor ipatasertib or
placebo in combination with paclitaxel as first-line che-
motherapy in metastatic TNBC. The trial demonstrated
amodest but significant increase inmedian PFS from 4.9 to
6.2 months with the addition of ipatasertib. Preliminary OS
data also suggested a trend toward improved OS, with an
approximately 5-month difference.26
The PAKT trial was designed to explore whether antitumor
activity of capivasertib might be enhanced in the subgroup
of patients with PIK3CA/AKT1/PTEN-altered tumors. Pre-
clinical studies demonstrated increased sensitivity in
models with activation of PI3K or AKT1 and/or deletions of
PTEN.16,18,19 Central assessment of PIK3CA/AKT1/PTEN
alterations by NGS was successful in 80% of patients in this
trial, which is similar to the NGS success rate in the LOTUS
trial (83%).26 A majority of samples were obtained from
primary tumors (82%). The diagnostic prevalence of
PIK3CA/AKT1/PTEN alterations in PAKT was 25%. There
was no significant difference in the incidence of PIK3CA/
AKT1/PTEN alterations between primary tumor samples
and tissue from metastases (x2 P = .359). This is com-
parable to the results of the METABRIC study, where 23%
of patients with TNBC demonstrated PIK3CA/AKT1/PTEN
alterations.6 In contrast, the diagnostic prevalence of
PIK3CA/AKT1/PTEN alterations in the LOTUS trial was
higher, at 41%.25 Possible explanations might include
differences in NGS assays and variant calling, preselection
of patients known to have pathway variants, or differences
in patient populations. In this context, it is noteworthy that
nearly half of the patients in the LOTUS trial were of Asian
ethnicity, compared with 13% in PAKT.
The PAKT trial strongly suggests that the benefits of AKT
inhibition might be largely limited to the subgroup of pa-
tients with PIK3CA/AKT1/PTEN alterations, although an OS
benefit cannot be excluded in patients with nonaltered
tumors. Cox proportional hazards models confirmed a sig-
nificant interaction between PIK3CA/AKT1/PTEN alter-
ations and treatment (P = .04).
Although this subgroup is small, and results have to be
interpreted with caution, the PIK3CA/AKT1/PTEN-altered
and -nonaltered results are further supported by the LOTUS
trial, which showed a similar but nonsignificant trend for
PFS, with an HR of 0.44 in patients with PIK3CA/AKT1/
PTEN alterations compared with an HR of 0.76 in
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FIG 2. Kaplan-Meier plot of progression-free survival (PFS) in (A) intent-to-treat population, (B) PIK3CA/AKT1/PTEN-altered subgroup, and (C) PIK3CA/AKT1/
PTEN-nonaltered subgroup. HR, hazard ratio; PFS, progression-free survival. (*) One-sided predefined significance level, P = .10.
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nonaltered tumors.25 Median OS was 23.1 months with
ipatasertib versus 16.2 months with placebo (HR, 0.65;
95% CI, 0.32 to 1.30) in patients with PIK3CA/AKT1/PTEN-
altered tumors.26 Although these findings from PAKT and
LOTUS have to be interpreted with caution because of their
small sample sizes, the fact that 2 independent trials
performed with different AKT inhibitors demonstrate
comparable results adds substantial weight to these
observations.
The combination of capivasertib plus paclitaxel was gen-
erally well tolerated. Most common AEs were GI effects,
particularly diarrhea, which was generally mild or moder-
ate, clinically manageable, and rapidly reversible; the
protocol specified guidelines for symptomatic diarrhea, but
prophylactic antidiarrheal medication was not recom-
mended; this might be revisited for future studies.
Hyperglycemia was more commonly observed with cap-
ivasertib but rarely had sequelae; of note, patients with
clinically significant abnormalities of glucose metabolism
were excluded. On the basis of our experience, inclusion of
patients with well-controlled diabetes might be considered
future trials. Overall, the toxicity profile seemed comparable
with those of other AKT inhibitors25 and was largely limited
to the known class effects of AKT inhibition. The favorable
tolerability profile was also reflected in the comparable
dose-intensity in both arms, despite a higher frequency of
dose modifications with capivasertib.
Despite the limitations mainly resulting from the sample
size and lack of adjustment for multiple testing (for the ITT
population and the PIK3CA/AKT1/PTEN-altered sub-
group), the PAKT study is one of few trials to demonstrate
PFS and OS benefits inmetastatic TNBC. The numbers and
TABLE 4. Primary and Secondary Efficacy End Points
End Point
ITT Population PIK3CA/AKT1/PTEN-Altered Subgroup
Paclitaxel + Capivasertib Paclitaxel + Placebo Paclitaxel + Capivasertib Paclitaxel + Placebo
ORR
No. of patients* 66 66 17 11
No. (%)† 23 (34.8) 19 (28.8) 6 (35.3) 2 (18.2)
2-sided P .58 .42
Clinical benefit rate
No. of patients‡ 70 70 17 11
No. (%)† 29 (41.4) 26 (37.1) 9 (52.9) 3 (27.3)
2-sided P .73 .25
Duration of response
No. of patients§ 23 19 6 2
Median (95% CI), months 7.6 (5.6 to 12.5) 7.3 (3.5 to 9.1) 13.3 (8.9 to NR) 3.5 (3.5 to NR)
2-sided P .57 .08
PFS
Median (95% CI), months 5.9 (3.8 to 7.5) 4.2 (3.5 to 5.2) 9.3 (3.7 to 17.7) 3.7 (1.9 to 5.9)
HR (95% CI) 0.74 (0.50 to 1.08) 0.30 (0.11 to 0.79)
P
1-sided .06
2-sided .11 .01
OS
Median (95% CI), months 19.1 (10.9 to 20.9) 12.6 (10.4 to 16.9) NR (10.2 to NR) 10.4 (4.0 to NR)
HR (95% CI) 0.61 (0.37 to 0.99) 0.37 (0.12 to 1.12)
P
1-sided .02
2-sided .04 .07
Abbreviations: HR, hazard ratio; ITT, intent to treat; NR, not reached; ORR, objective response rate; OS, overall survival; PFS, progression-free
survival.
*No. of patients in the ITT population with measurable disease at baseline.
†All percentages are based on the total No. of patients in that arm based on the specified population.
‡No. of patients in the ITT population.
§No. of patients with measurable disease at baseline and an objective response.
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types of subsequent treatments after progression were
comparable between treatment groups, suggesting the
observed differences resulted from the study treatment.
Together with the LOTUS trial, the PAKT study provides
important evidence that AKT inhibition might be able to
improve patient outcomes in this difficult-to-treat subtype of
breast cancer, but confirmatory and adequately powered
phase III trials are required. On the basis of the current
data, paclitaxel should be considered as the chemotherapy
backbone for future studies, but other chemotherapy
combinations may also be explored. Capivasertib is being
further investigated for the treatment of TNBC in a phase III
randomized trial (NCT03997123). Prospectively planned
biomarker analyses based on preclinical observations
support selection of patients with PIK3CA/AKT1/PTEN
alterations for future studies.
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FIG A1. Biomarker prevalence. Prevalence based on all available diagnostic data. Each vertical set of blocks represents an individual patient’s tumor. Dark
blue blocks represent PTEN-altered by NGS; green blocks represent AKT1-mutant by NGS; red blocks represent PIK3CA-mutant by NGS; gray blocks
represent samples with no corresponding data available (assay failure or insufficient sample for testing). The top row shows whether samples are classified as
PIK3CA/AKT1/PTEN-altered (yellow) or PIK3CA/AKT1/PTEN-non-altered (light blue). NGS, next-generation sequencing.
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FIG A2. Subgroup analysis of progression-free survival. n is the number of patients who have a progression event
(documented progression or death) in each subgroup. N is the number of patients in each subgroup. Dashed lines
represent the hazard ratio and its 95% confidence interval for the all patients population. HR, hazard ratio; IDC,
invasive ductal carcinoma; ILC, invasive lobular carcinoma.
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FIG A3. Kaplan-Meier plot of progression-free survival (PFS) based on a blinded independent central
review. (A) Intention-to-treat population; (B) PIK3CA/AKT1/PTEN-altered subgroup; (C) PIL2CA/AKT1/
PTEN non-altered subgroup. CI, Confidence interval; HR, Hazard Ratio; mths, months; PFS,
Progression-free survival; NR, not reached.
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